Beschreibung
Letrozole 2.5 mg
Brand: Magnus Pharmaceuticals
Content: 50 tablets | 2.5 mg per tablet
Price: €39
Manufactured in: Europe
🧪 Product Overview
Letrozole 2.5 mg is a third-generation, non-steroidal aromatase inhibitor (AI) that irreversibly binds the CYP19 enzyme to suppress estrogen biosynthesis. Designed for advanced hormone modulation studies, it supports research into testosterone enhancement, post-cycle therapy (PCT), fertility pathways, and estrogen-receptor positive (ER+) tumor models.
A single 2.5 mg oral dose reduces serum estradiol (E₂) by 60–80% within 24 hours and maintains suppression for ≥48 hours, supported by a 42–48 hour mean half-life. In male models, letrozole increases LH, FSH, and endogenous testosterone while improving sperm count—without impacting adrenal androgens. Exposure is prohibited in all WADA-sanctioned settings.
✅ Key Research Highlights
Potent estrogen suppression:
≥80% reduction in serum estradiol (E₂) achieved within 24 h after 2.5 mg dosing [NCBI]
Endogenous testosterone boost:
Studies in male infertility show ↑ LH, FSH, T, and sperm quality after 8–16 weeks [ScienceDirect, PMC]
Pharmacokinetics:
Oral bioavailability ~100%, t½ ≈ 42–48 h, steady-state in 2–6 weeks [DrugBank, PMC]
Common side effects:
Hot-flushes, joint discomfort, fatigue, and menopausal-like symptoms [NHS, Breast Cancer Now]
Long-term risks:
Reductions in bone-mineral density and lipid imbalances documented in chronic protocols [PMC]
🧬 Suggested Laboratory Applications
-
Aromatase inhibition and estrogen suppression modeling
-
Testosterone recovery and hormonal modulation
-
Fertility enhancement trials in male hypogonadism
-
PCT protocols in anabolic research models
-
ER+ breast cancer resistance pathways (e.g. tamoxifen-resistant models)
📊 Technical Specifications
| Field | Data |
|---|---|
| Chemical Name | Letrozole |
| Chemical Formula | C<sub>17</sub>H<sub>11</sub>N<sub>5</sub> |
| Synonyms | Femara, CGP 57148, 4,4′-((1H-1,2,4-triazol-1-yl)methylene)dibenzonitrile |
| Molecular Weight | 285.3 g/mol |
| CAS Number | 112809-51-5 |
| Half-life | 42–48 hours |
| Detection Window | ≥2 days (varies by protocol) |
| Documented Benefits | ↓ estrogen ≥80%, ↑ LH/FSH, ↑ T, fertility support, anti-ER+ tumor adjunct |
| Main Risks | ↓ BMD, joint pain, lipid alterations, fatigue, menopausal symptoms |
| Total Active Compound | 125 mg per carton (2.5 mg × 50 tablets) |
| Shelf-life | 36 months (manufacturer specification) |
❄️ PubChem-Supported Research Insights
-
Irreversibly inhibits aromatase enzyme (CYP19)
-
Maintains ≥80% estradiol suppression for 48+ hours
-
Improves testosterone-to-estradiol ratio without adrenal disruption
-
Increases LH and FSH in male fertility research
-
Used as an adjunct in tamoxifen-resistant ER+ tumor protocols
⚠️ Documented Research Side Effects
-
Hot flashes and joint discomfort common
-
Potential for bone-density loss with chronic use
-
Altered lipid profiles: ↑ LDL / ↓ HDL
-
Fatigue and hormonal mood shifts
-
High doping detectability under WADA S4 classification
🧯 Handling & Compliance
For Research Use Only — Not for human or veterinary use
Store at 15–25 °C, protect from light and moisture
Purchase confirms qualified researcher status
Listed on WADA Prohibited List S4 — any exposure may yield a positive doping result
There are no reviews yet.
